Market Place
Sourcing Support
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
10 Jul 2024 //
GLOBENEWSWIRE
J&J, Legend`s Carvykti extends lives in multiple myeloma trial
03 Jul 2024 //
PRESS RELEASE
Legend`s CARVYKTI Early Use, Subgroup Data In Multiple Myeloma
03 Jun 2024 //
BUSINESSWIRE
Legend Car-T Multiple Myeloma: Leadership Highlighted Asco Eha Featured
23 May 2024 //
BUSINESSWIRE
CARVYKTI Approved In EU For 2L Relapsed/Refractory Myeloma
22 Apr 2024 //
BUSINESSWIRE
Legend, J&J tap Novartis for commercial production of Carvykti
29 Mar 2024 //
FIERCE PHARMA
CARVYKTI Receives Recommendation from FDA Oncologic Drugs Advisory Committee
15 Mar 2024 //
BUSINESSWIRE
Legend CEO offers preview of high-stakes FDA adcomm for Carvykti
11 Mar 2024 //
FIERCE PHARMA
EMA recommends approval of Carvykti in earlier lines of multiple myeloma
24 Feb 2024 //
ENDPTS
FDA calls external review of J&J, Legend`s Carvykti
23 Jan 2024 //
FIERCE PHARMA
Legend Bio to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
FDA adds Carvykti`s secondary cancer risk to boxed warning
21 Dec 2023 //
FIERCE PHARMA
Study Showed Meaningful Improvements Following Treatment with CARVYKTI
11 Dec 2023 //
BUSINESSWIRE
Cilta-cel Reduced Risk of Disease Progression in CARTITUDE-4 Study
05 Jun 2023 //
BUSINESSWIRE
Data Leak Shows J&J’s and Legend’s Carvykti Exceeds Expectations
20 Apr 2023 //
BIOSPACE
Legend Announces PIII CARTITUDE-4 Study of CARVYKTI Has Met Primary Endpoint
27 Jan 2023 //
BUSINESSWIRE
Sales of J&J, Legend cell therapy plateau amid production challenges
25 Jan 2023 //
BIOPHARMADIVE
ASH: BCMA battle heats up as Gracell dazzles with 100% ORR in MM
12 Dec 2022 //
FIERCEBIOTECH
Legend Biotech Announces FDA Clearance of IND Application for LB2102
21 Nov 2022 //
PRESS RELEASE
Legend CEO spells out path to $5B in sales for myeloma CAR-T therapy Carvykti
19 Nov 2022 //
ENDPTS
Legend Biotech Announces Participation in Upcoming Investor Conferences
04 Nov 2022 //
BUSINESSWIRE
Legend Biotech Shares Data from Comprehensive Cilta-Cel Clinical Develop
03 Nov 2022 //
PRESS RELEASE
CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry
27 Oct 2022 //
PRESS RELEASE
Why Legend Biotech`s Shares Jumped 14.2% On Tuesday
18 Oct 2022 //
FOOL
J&J, Legend double CAR-T manufacturing investment to $500M
07 Oct 2022 //
FIERCEPHARMA
Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022
15 Sep 2022 //
BUSINESSWIRE
Two years after stepping down, Frank Zhang is back as Legend chair
05 Aug 2022 //
ENDPTS
Legend Biotech looks to raise $250M amid CAR-T rollout
26 Jul 2022 //
FIERCEPHARMA
Legend scraps early stage CAR-T 6 weeks after FDA hold lifted
08 Jul 2022 //
FIERCEBIOTECH
FDA Clears IND of Legend Biotech for Solid Tumor CAR-T, LB1908
03 Jun 2022 //
BUSINESSWIRE
FDA lifts hold on Legend Biotech`s follow-up CAR-T targeting CD4+
02 Jun 2022 //
ENDPTS
Legend Biotech Reports Q1 2022 Financial Results and Recent Highlights
01 Jun 2022 //
BUSINESSWIRE
Legend Biotech to Host Investors at the 2022 ASCO
31 May 2022 //
BUSINESSWIRE
CARVYKTI Granted Conditional Approval by EC for r/r Multiple Myeloma
26 May 2022 //
BUSINESSWIRE
ASCO: J&J, Legend reveal more CAR-T data from Carvykti
26 May 2022 //
FIERCEPHARMA
Legend Biotech to Highlight Continued Progress in Multiple Myeloma
18 May 2022 //
BUSINESSWIRE
Legend Biotech Announces Participation in Upcoming Investor Conferences
06 May 2022 //
BUSINESSWIRE
Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen
21 Apr 2022 //
BUSINESSWIRE
Frank Fan resigns from Legend post CAR-T therapy approval
04 Apr 2022 //
ENDPTS
Legend Biotech CSO abruptly quits from J&J`s CAR-T partner
02 Apr 2022 //
FIERCEBIOTECH
CARVYKTI Receives Positive CHMP Opinion for r/r Multiple Myeloma
25 Mar 2022 //
BUSINESSWIRE
Legend Biotech Reports Q4 and FY 2021 Financial Results
18 Mar 2022 //
BUSINESSWIRE
Legend CEO eyes earlier Carvykti use, cheaper CAR-T
09 Mar 2022 //
FIERCEPHARMA
CARVYKTI Receives FDA Approval in Relapsed or Refractory Multiple Myeloma
01 Mar 2022 //
BUSINESSWIRE
Legend Biotech Announces Preliminary Results for Year Ended Dec 31, 2021
18 Feb 2022 //
BUSINESSWIRE
Legend`s early-stage CAR-T on FDA hold after single patient dose
16 Feb 2022 //
FIERCEBIOTECH
Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collab with Janssen
11 Feb 2022 //
BUSINESSWIRE
J&J, Legend hope to avoid supply challenges with cilta-cel
13 Jan 2022 //
FIERCEPHARMA
Legend Biotech Corporation Announces Pricing of Public Offering
16 Dec 2021 //
BUSINESSWIRE
Legend Biotech Submits NDA to MHLW for BCMA CAR-T Therapy
07 Dec 2021 //
BUSINESSWIRE
Legend Biotech Announces Submission of NDA Japanese Regulatory for BCMA CAR-T
06 Dec 2021 //
PRESS RELEASE
Legend Biotech Reports Q3 2021 Financial Results and Recent Highlights
16 Nov 2021 //
BUSINESSWIRE
Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T
04 Nov 2021 //
BUSINESSWIRE
FDA extends review of J&J, Legend`s cell therapy for multiple myeloma
02 Nov 2021 //
BIOPHARMADIVE
Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel
01 Nov 2021 //
BIOSPACE
J&J plots tailored patient support program for upcoming CAR-T
22 Oct 2021 //
FIERCEPHARMA
Legend Biotech Begins PI Trial of Anti-CD4 CAR-T Therapy for r/r T-Cell Lymphoma
13 Sep 2021 //
BUSINESSWIRE
Legend Biotech to Participate in 19th Annual Morgan Stanley Global Conference
30 Aug 2021 //
BUSINESSWIRE
Legend Biotech Reports Second Quarter 2021 Financial Results and Highlights
23 Aug 2021 //
BUSINESSWIRE
J&J, Legend unveil plans for Belgian cell therapy manufacturing facility
26 Jun 2021 //
ENDPTS
